Skip to main content
. 2020 Mar 9;5(4):485–493. doi: 10.1016/j.ekir.2020.01.011

Figure 2.

Figure 2

Hematologic response status after first- and second-line treatment. BOR, bortezomib; CR, complete response; HDM/SCT, high-dose melphalan/stem cell transplantation; LEN, lenalidomide; MM, multiple myeloma; NR, no response; POM, pomalidomide; PR, partial response; VGPR, very good partial response.